On August 5, 2024, Hutchmed (China) Limited announced that it had granted stock options and awards to executive director Dr. Su Wei Guo and other employees under the share option plan and long term incentive plan adopted in 2015. This is to attract and retain top talent and ensure that the company can recruit and retain these talents. Dr. Su was granted 1,405,767 ordinary shares of stock options with an exercise price of HKD 29.20 per share, valid until August 4, 2034. The exercise of the share options is subject to specific performance targets and restrictions on refund policies. In addition, the company has also granted 200,000 ordinary shares of stock options to an employee, as well as performance-based long-term incentive awards to Dr. Su and Mr. Zheng Zefeng. Hutchmed (China) is a biomedical company focused on discovering, developing and commercializing drugs for the treatment of cancer and immune diseases.

On August 5, 2024, Hutchmed (China) Limited announced that it had granted stock options and awards to executive director Dr. Su Wei Guo and other employees under the share option plan and long term incentive plan adopted in 2015. This is to attract and retain top talent and ensure that the company can recruit and retain these talents. Dr. Su was granted 1,405,767 ordinary shares of stock options with an exercise price of HKD 29.20 per share, valid until August 4, 2034. The exercise of the share options is subject to specific performance targets and restrictions on refund policies. In addition, the company has also granted 200,000 ordinary shares of stock options to an employee, as well as performance-based long-term incentive awards to Dr. Su and Mr. Zheng Zefeng. Hutchmed (China) is a biomedical company focused on discovering, developing and commercializing drugs for the treatment of cancer and immune diseases.